8-K: BBOT Debuts on Nasdaq After Successful SPAC Merger
Sentiment:
Business Combination Completion
BridgeBio Oncology Therapeutics, Inc. (BBOT) has successfully completed its business combination with Helix Acquisition Corp. II, debuting on the Nasdaq Global Market with approximately $382 million in gross proceeds.
Capital raiseA private investment in public equity (PIPE) closed concurrently with the business combination, raising $261 million.The PIPE was led by Cormorant Asset Management and included premier institutional investors such as ADAR1 Capital Management, BC Capital, investment funds affiliated with Deerfield Management Company, Enavate Sciences, Eventide Asset Management, Novo Holdings A/S, Octagon Capital, Omega Funds, Paradigm BioCapital Advisors, StemPoint Capital LP, Surveyor Capital (a Citadel company), and Wellington Management.The combined company received approximately $120 million from the former Helix Trust account, reflecting a 39% redemption rate.Total gross proceeds from the business combination and PIPE amounted to approximately $382 million.
Better than expectedThe business combination successfully closed, securing significant capital.The redemption rate of approximately 39% was notably low, indicating strong investor confidence.The company secured $382 million in gross proceeds, including a substantial PIPE investment, providing ample funding for pipeline acceleration.
Summary
- The business combination with Helix Acquisition Corp. II was completed on August 11, 2025.
- Helix changed its name to BridgeBio Oncology Therapeutics, Inc. (BBOT) and its common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol BBOT on August 12, 2025.
- The transaction generated approximately $382 million in gross proceeds, comprising $120 million from Helix's trust account and $261 million from a private investment in public equity (PIPE).
- The redemption rate for Helix Class A shares was approximately 39%, noted as the second lowest for a biotech de-SPAC transaction since 2022.
- The combined company is expected to have approximately $490 million in cash, cash equivalents, and marketable securities post-closing.
- Net proceeds will be used to accelerate the development of BBOT's RAS-targeted oncology drug candidates, including BBO-8520 (KRASG12C inhibitor), BBO-10203 (RAS-PI3K interaction inhibitor), and BBO-11818 (panKRAS inhibitor).
- BBOT incurred a net loss of $50.5 million for the six months ended June 30, 2025, and had an accumulated deficit of $273.0 million as of June 30, 2025.
- Research and development expenses increased by $12.4 million (34.7%) to $48.1 million for the six months ended June 30, 2025, compared to $35.7 million for the same period in 2024.
- General and administrative expenses increased by $1.5 million (41.6%) to $5.2 million for the six months ended June 30, 2025, compared to $3.6 million for the same period in 2024.
- Interest income increased by $1.7 million (96.2%) to $3.5 million for the six months ended June 30, 2025, compared to $1.8 million for the same period in 2024.
Sentiment
Score: 8
Explanation: The successful completion of the business combination with a low redemption rate and significant capital infusion provides a strong financial foundation for advancing a promising oncology pipeline. While the company is still pre-revenue and incurring losses, the funding extends its operational runway and supports key development programs, indicating a positive outlook for future growth and value creation.
Positives
- Successful completion of the business combination and Nasdaq listing provides a strong platform for growth.
- A low redemption rate of approximately 39% for Helix Class A shares indicates strong investor confidence in the transaction and the combined entity.
- Significant gross proceeds of $382 million, including a $261 million PIPE, provide substantial capital to fund operations and accelerate pipeline development.
- The company's pipeline includes three clinical-stage RAS-targeted oncology drug candidates (BBO-8520, BBO-10203, BBO-11818) with novel mechanisms of action.
- Expected cash, cash equivalents, and marketable securities of approximately $490 million post-closing are projected to fund operations into 2027.
- Management expressed deep commitment to advancing transformative therapies and realizing the full potential of KRAS and PI3Ka inhibition.
Negatives
- The company has incurred significant operating losses and negative cash flows from operations since its inception.
- An accumulated deficit of $273.0 million was reported as of June 30, 2025.
- The company expects to incur additional losses and negative cash flows for the foreseeable future as it continues research and development.
- Reliance on a small number of third-party manufacturers for active pharmaceutical ingredients and formulated drugs poses a supply chain risk.
Risks
- Changes in domestic and foreign business, market, financial, political, and legal conditions.
- Failure to realize the anticipated benefits of the business combination.
- Risks relating to any legal proceedings that may be instituted against PubCo or others following the announcement of the business combination.
- Uncertainty of the projected financial information with respect to PubCo.
- Risks related to the approval of PubCo's product candidates and the timing of expected regulatory and business milestones, including enrollment and data readouts for clinical trials.
- Ability to negotiate definitive contractual arrangements with potential customers.
- Impact of competitive product candidates.
- Ability to obtain sufficient supply of materials.
- Global economic and political conditions.
- Effects of competition on PubCo's future business.
- PubCo's ability to maintain the listing of its Common Stock on Nasdaq.
- Uncertainty regarding outcomes of PubCo's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidates.
- Risks associated with PubCo's efforts to commercialize its product candidates.
- PubCo's ability to maintain its existing agreements with third parties and to negotiate and enter into new definitive agreements on favorable terms, if at all.
- Intellectual property-related claims.
- PubCo's ability to attract and retain qualified personnel.
- PubCo's ability to source the raw materials for its product candidates.
Future Outlook
The combined company expects to use the net proceeds from the business combination to accelerate the development of its pipeline of RAS-targeted oncology drug candidates. It anticipates incurring additional losses and negative cash flows for the foreseeable future as it advances product candidates, expands its pipeline, seeks regulatory approvals, and prepares for commercialization. The company believes its existing cash, cash equivalents, and marketable securities, along with the financing from the de-SPAC transaction, will support operations for at least one year from June 30, 2025, and into 2027.
Management Comments
- "The successful completion of our business combination, with a relatively low redemption rate of approximately 39%, is a pivotal milestone that underscores the strong conviction of our investors in our vision. With meaningful progress across all three of our pipeline programs, we are entering this next chapter as a public company with significant momentum. We are deeply committed to advancing transformative therapies for patients facing deadly cancers mediated by the RAS pathway, and believe we are well-positioned to deliver meaningful value to patients as we work towards realizing the full potential of KRAS and PI3Ka inhibition." Eli Wallace, PhD, Chief Executive Officer of BBOT.
- "BBOT has made tremendous progress advancing its RAS-targeted therapeutics in the clinic. BBOT's drug candidates could provide significantly more patient benefit through optimizing target coverage and through exciting new combination therapies. The completion of the business combination marks another important milestone in BBOTs journey. On behalf of BBOTs board and management team I would like to welcome our new investors and thank them for their strong support." Frank McCormick, PhD, Chairman of BBOT Board.
- "Cormorant is thrilled to support BBOT through its Helix SPAC platform as the company advances its innovative portfolio of therapeutic agents targeting the two most commonly mutated oncogenes in human cancer, KRAS and PI3K. BBOTs next generation KRAS ON inhibitors and its highly novel PI3K Breaker, which disrupts KRAS-driven PI3K activation, hold great promise to transform the treatment landscape for solid tumors driven by these oncogenes. Helix is extremely grateful to work with a stellar syndicate of investors within our trust, such as Adage Capital Management LP, BC Capital Management Ltd., BlackRock Advisors LLC, Laurion Capital Management LP, Millenium Management LLC, Octagon Capital Advisors LP, Oppenheimer, Silver Arc Capital Management LLC, Stempoint Capital LP, and Woodline Partners LP, as well as BBOTs outstanding team to deliver these much-needed therapeutic options to patients. We are proud that Helix provides a capital market solution uniquely poised to help companies such as BBOT rapidly and thoughtfully advance multiple parallel clinical programs." Bihua Chen, Founder and CEO of Cormorant, and CEO of Helix.
Industry Context
The successful de-SPAC transaction and significant capital raise position BBOT to accelerate development in the highly competitive and rapidly evolving oncology space, particularly in RAS-pathway and PI3K malignancies. The focus on novel small molecule therapeutics for KRAS and PI3K inhibition aligns with a key trend in precision oncology, targeting prevalent oncogenes. The low redemption rate for the SPAC transaction suggests strong investor confidence in BBOT's pipeline and strategy, distinguishing it in a market where SPAC redemptions can be high.
Comparison to Industry Standards
- The 39% redemption rate for Helix Class A shares is noted as the second lowest for a biotech de-SPAC transaction since 2022, indicating strong investor support compared to industry averages for similar transactions.
- BBOT's drug candidates (BBO-8520, BBO-10203, BBO-11818) are described as having novel mechanisms of action (e.g., direct KRASG12C ON/OFF state inhibition, RAS-PI3K interaction inhibition, panKRAS inhibition with broad selectivity), suggesting potential differentiation from existing or developing therapies in the oncology market.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Eli Wallace (BBOT) | Eli Wallace (PubCo) | August 11, 2025 | Continuation of role in combined entity. |
| Chief Financial Officer | NA | Uneek Mehra | August 11, 2025 | Appointment in combined entity. |
| Chief Scientific Officer | Pedro Beltran (BBOT) | Pedro Beltran (PubCo) | August 11, 2025 | Continuation of role in combined entity. |
| Chief Medical and Development Officer | Yong Ben (BBOT) | Yong Ben (PubCo) | August 11, 2025 | Continuation of role in combined entity. |
| Board Member (Class I) | NA | Frank McCormick | August 11, 2025 | Appointment to PubCo Board. |
| Board Member (Class I) | NA | Michelle Doig | August 11, 2025 | Appointment to PubCo Board. |
| Board Member (Class II) | NA | Bihua Chen | August 11, 2025 | Appointment to PubCo Board. |
| Board Member (Class II) | NA | Neil Kumar | August 11, 2025 | Appointment to PubCo Board. |
| Board Member (Class II) | NA | Raymond Kelleher | August 11, 2025 | Appointment to PubCo Board. |
| Board Member (Class III) | NA | Jake Bauer | August 11, 2025 | Appointment to PubCo Board. |
| Board Member (Class III) | NA | Praveen Tipirneni | August 11, 2025 | Appointment to PubCo Board. |
| Board Member (Class III) | NA | Eli Wallace | August 11, 2025 | Appointment to PubCo Board. |
| Independent Registered Public Accounting Firm | WithumSmith+Brown, PC (for Helix) | Deloitte & Touche LLP (for PubCo) | August 11, 2025 | Dismissal of previous auditor post-Business Combination, engagement of BBOT's prior auditor. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Corporate Name Change | Helix Acquisition Corp. II changed its corporate name to BridgeBio Oncology Therapeutics, Inc. (PubCo). | August 11, 2025 | Reflects the new identity of the combined entity post-merger. |
| Redomiciliation | Helix de-registered from the Cayman Islands and domesticated as a Delaware corporation. | August 11, 2025 | Aligns corporate structure with U.S. operations and regulatory framework. |
| Certificate of Incorporation Amendment | PubCo adopted a new Certificate of Incorporation, increasing authorized common stock to 500,000,000 shares and preferred stock to 10,000,000 shares, and classifying the Board into three staggered terms. | August 11, 2025 | Provides flexibility for future equity issuances and establishes a staggered board structure, potentially impacting shareholder influence on board composition. |
| Bylaws Amendment | PubCo approved and adopted new Bylaws, including provisions for lock-up agreements for certain stockholders and rules for stockholder meetings. | August 11, 2025 | Establishes operational procedures and transfer restrictions for certain shares, impacting liquidity for initial investors. |
| Equity Incentive Plan Adoption | Approved the BridgeBio Oncology Therapeutics, Inc. 2025 Stock Option and Incentive Plan, reserving 5,373,641 shares initially, with annual increases. | August 11, 2025 | Provides a framework for equity compensation to attract and retain key personnel, aligning their interests with stockholders. |
| Employee Stock Purchase Plan Adoption | Approved the BridgeBio Oncology Therapeutics, Inc. 2025 Employee Stock Purchase Plan, reserving 895,607 shares initially, with annual increases. | August 11, 2025 | Encourages broader employee ownership and participation in the company's success. |
| Executive Severance Plan Adoption | Adopted the Executive Severance Plan for Tier 1, 2, and 3 executives, outlining severance benefits upon qualified termination events. | August 11, 2025 | Provides financial security for key executives, potentially aiding retention and smooth transitions. |
| Senior Executive Cash Incentive Bonus Plan Adoption | Adopted the Senior Executive Cash Incentive Bonus Plan, linking bonuses to corporate performance goals and individual objectives. | August 11, 2025 | Establishes a structured bonus system to incentivize executive performance. |
| Non-Employee Director Compensation Policy Adoption | Adopted a Non-Employee Director Compensation Policy, including cash retainers and equity awards (Initial and Annual Awards) with specific vesting schedules and limits. | August 11, 2025 | Standardizes and formalizes compensation for non-employee directors, ensuring competitive remuneration and alignment with long-term company performance. |
| Code of Ethics Adoption | Approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers, agents, and representatives. | August 11, 2025 | Reinforces ethical standards and legal compliance across the organization, including whistleblower protections. |
| Indemnification Agreements | Entered into indemnification agreements with each of its directors and officers and purchased D&O liability insurance. | August 11, 2025 | Provides protection for directors and officers against liabilities, aiding in attracting and retaining qualified individuals. |
Legal Proceedings
- No new or ongoing legal proceedings are detailed in this filing, though the Proxy Statement/Prospectus contains further information on legal proceedings for Helix and BBOT.
Related Party Transactions
- BridgeBio Pharma, Inc. and its controlled entities (collectively, BridgeBio Pharma) are related parties of BBOT.
- Prior to April 30, 2024, BBOT was majority-owned and controlled by BridgeBio Pharma.
- All shares of Series Seed and Series A redeemable convertible preferred stock issued by BBOT through June 30, 2025, remain owned by BridgeBio Pharma.
- BBOT recognized $0.2 million (Q2 2025) and $0.4 million (H1 2025) in research and development expenses and $0.2 million (Q2 2025) and $0.4 million (H1 2025) in general and administrative expenses for services provided by BridgeBio Pharma under a transition services agreement.
- For Q2 2024 and H1 2024, BBOT recognized $2.5 million and $8.0 million in research and development expenses and $0.8 million and $2.4 million in general and administrative expenses, respectively, for services provided by BridgeBio Pharma.
- For Q2 2024 and H1 2024, BBOT recognized $0.3 million in income from services rendered to BridgeBio Pharma under the transition services agreement.
- Allocated general and administrative expenses from BridgeBio Pharma (prior to April 30, 2024) were presented as deemed contributions from BridgeBio Pharma to BBOT.
- Related party payables of $19.7 million were extinguished by converting them into Series A redeemable convertible preferred stock issued to BridgeBio Pharma during H1 2024.
- A $3.7 million deemed contribution from BridgeBio Pharma was recognized from the forgiveness of related party payables during H1 2024.
- Certain investment vehicles managed by Cormorant Asset Management, LP are significant beneficial owners (22.6%) and participated in the PIPE investment and Helix Support Agreement.
- BridgeBio Pharma LLC is a significant beneficial owner (17.5%).
- Entities affiliated with Deerfield Management Company, L.P. are significant beneficial owners (6.2%) and participated in the PIPE investment.
Stakeholder Impact
- Shareholders: Existing Helix shareholders who did not redeem their shares now hold PubCo Common Stock. BBOT stockholders received PubCo Common Stock based on a conversion ratio. PIPE investors acquired PubCo Common Stock. All shareholders are subject to new corporate governance documents (Certificate of Incorporation, Bylaws) and lock-up agreements for certain holders. Potential for value creation from accelerated pipeline development.
- Employees: Key executives (CEO, CFO, CSO, CMDO) have new employment agreements with updated salaries and bonus targets. New equity incentive and employee stock purchase plans are in place, aligning employee interests with company performance. An executive severance plan provides benefits for qualified terminations.
- Management: A new board of directors and executive management team for PubCo have been appointed. Indemnification agreements provide protection for directors and officers.
- Creditors: The company's liquidity position is significantly strengthened by the capital raise, potentially reducing credit risk.
- Customers/Patients: The accelerated development of oncology drug candidates aims to bring new therapeutic options to patients with RAS-pathway malignancies.
Next Steps
- BBOT shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol BBOT on August 12, 2025.
- Accelerate the development of BBOT's pipeline of RAS-targeted oncology drug candidates (BBO-8520, BBO-10203, BBO-11818).
- Continue enrollment in the Phase 1 ONKORAS-101 trial for BBO-8520.
- Continue evaluation in the Phase 1 BREAKER-101 trial for BBO-10203.
- Continue enrolling patients in the Phase 1 KONQUER-101 trial for BBO-11818.
- Evaluate the potential impact of the One Big Beautiful Bill Act (enacted July 2025) on federal tax law and regulatory provisions.
- Evaluate the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Income Statement Expenses) for effective dates in 2025 and 2027, respectively.
- Evaluate the impact of ASU 2025-03 (Business Combinations) and ASU 2025-04 (Stock Compensation) for effective dates in 2027 and 2026, respectively.
Key Dates
| Date | Description |
|---|---|
| March 3, 2017 | Cooperative Research and Development Agreement (Leidos CRADA) entered with Leidos Biomedical Research, Inc. |
| May 22, 2018 | Cooperative Research and Development Agreement (LLNS CRADA) entered with Lawrence Livermore National Security, LLC. |
| July 7, 2022 | Limited Exclusive Patent License Agreements with LLNS for KRAS G12C inhibitors and PI3K breaker compounds entered. |
| August 5, 2022 | Patent License Agreements with The Frederick National Laboratory for Cancer Research entered. |
| December 20, 2023 | Patent License Agreement with The Frederick National Laboratory for Cancer Research for PanKRAS inhibitor entered. |
| April 25, 2024 | Eli Wallace's original offer of employment date. |
| April 29, 2024 | Pedro Beltran's Restrictive Covenants Agreement date. |
| April 30, 2024 | Eli Wallace's and Pedro Beltran's original offer of employment start date; BBOT Series B Preferred Stock financing completed; Board adopted Amendment No. 1 to 2016 Equity Incentive Plan. |
| May 1, 2024 | Eli Wallace's and Pedro Beltran's employment start date. |
| August 9, 2024 | Board approved FDA acceptance of PI3Ka Breaker IND. |
| August 12, 2024 | Yong Ben's original offer of employment date. |
| September 3, 2024 | Yong Ben's employment start date. |
| September 10, 2024 | Amendment to Eli Wallace's Employee Offer Letter regarding equity awards. |
| December 20, 2024 | Limited Exclusive Patent License Agreement with LLNS for Pan KRAS inhibitor entered. |
| February 28, 2025 | Business Combination Agreement date; Subscription Agreements for PIPE Investment entered into. |
| March 15th | Annual bonus payment deadline (of calendar year following bonus year). |
| March 29, 2025 | Extended deadline for UCSF Participation Right. |
| May 20, 2025 | Amendment No. 5 to LLNS CRADA. |
| June 13, 2025 | Uneek Mehra's original offer of employment date. |
| June 17, 2025 | Amendment No. 1 to Business Combination Agreement. |
| July 10, 2025 | Helix's definitive proxy statement/prospectus filed. |
| July 21, 2025 | Supplement to Helix's definitive proxy statement/prospectus filed. |
| July 2025 | The One Big Beautiful Bill Act was enacted in the United States. |
| August 4, 2025 | Helix shareholders approved the business combination and other proposals; Stockholders approved the 2025 Stock Option and Incentive Plan and 2025 Employee Stock Purchase Plan. |
| August 11, 2025 | Closing Date of Business Combination; Helix changed name to BridgeBio Oncology Therapeutics, Inc.; PubCo Common Stock listed on Nasdaq; A&R Registration Rights Agreement and Lock-up Agreements entered; Indemnification agreements entered; 2025 Stock Option and Incentive Plan and 2025 Employee Stock Purchase Plan became effective; Executive Severance Plan, Senior Executive Cash Incentive Bonus Plan, and Non-Employee Director Compensation Policy adopted; New Code of Ethics approved and adopted. |
| August 12, 2025 | PubCo Common Stock expected to begin trading on Nasdaq under BBOT. |
| December 22, 2025 | Extended LLNS CRADA expiration date. |
| January 1, 2026 | Automatic increase in shares reserved for 2025 Stock Option and Incentive Plan and 2025 Employee Stock Purchase Plan begins. |
| January 1, 2027 | Effective date for ASU 2024-03 (Income Statement – Reporting Comprehensive Income). |
Recommendation
buyThe successful completion of the business combination, coupled with a low redemption rate and a substantial capital infusion of $382 million, significantly de-risks the company's near-term funding needs. This capital is earmarked to accelerate the development of a promising clinical-stage oncology pipeline targeting high-value RAS and PI3K malignancies with novel mechanisms of action. While the company is pre-revenue and will continue to incur losses, the extended cash runway into 2027 provides ample time to advance its programs and achieve critical milestones. The strong institutional investor participation in the PIPE further validates the company's potential. This event marks a positive inflection point, positioning BBOT for significant long-term growth in the biotech sector.
Keywords
BridgeBio Oncology Therapeutics, BBOT, Helix Acquisition Corp. II, SPAC, Business Combination, Nasdaq Listing, Oncology, RAS-pathway malignancies, KRAS inhibitor, PI3K inhibition, BBO-8520, BBO-10203, BBO-11818, Clinical-stage biopharmaceutical, PIPE Investment, Drug development, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.